

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CF PharmTech, Inc. **長風藥業股份有限公司**

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT INCLUSION AS A CONSTITUENT STOCK OF THE HANG SENG COMPOSITE INDEX

This announcement is made by CF PharmTech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, according to the results of the quarterly review of the Hang Seng Family of Indexes for the period ended December 31, 2025, announced by Hang Seng Indexes Company Limited on February 13, 2026, the Company has been selected and will be included as a constituent stock of the Hang Seng Composite Index, with such changes taking effect from March 9, 2026.

The Hang Seng Composite Index offers a comprehensive Hong Kong market benchmark that covers about 95% of the total market capitalization of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited.

The Board is of the view that the inclusion of the Company as a constituent stock of the Hang Seng Composite Index reflects the capital market's recognition of the Group's leading position in the respiratory disease treatment market and its capabilities across its comprehensive inhalation drug delivery platform. The Board expects that such inclusion will help expand the shareholder base of the Company and increase the trading liquidity of the shares of the Company, thereby further enhancing the Company's reputation and investment value in the capital markets.

ABOUT THE COMPANY

As a global innovator in inhalation drug delivery technology, CF PharmTech, Inc. is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company specializes in the development of complex inhalation formulations with high barriers to entry and is a platform-based innovative pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, global regulatory filing and commercialization.

Leveraging its fully self-developed, globally integrated end-to-end capabilities — from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to siRNA nucleic acid delivery platforms, among others — the Company is systematically advancing its innovative pipeline for the markets in China, the United States and Europe. Its therapeutic areas encompass respiratory diseases (including asthma, chronic obstructive pulmonary disease and bronchiectasis) and nasal diseases (including allergic rhinitis and chronic rhinosinusitis), with strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders, as the Company pioneers precision drug delivery via the nose-to-brain pathway.

The Company has established an extensive multi-dimensional commercialization network in China and, through its globally compliant manufacturing systems and deepening international presence, is steadily advancing towards its goal of becoming a global innovative pharmaceutical enterprise.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing
*Chairperson, Executive Director and
Chief Executive Officer*

Hong Kong, February 16, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.